Canaccord analyst Kyle Mikson maintains a Buy rating and $50 price target on Guardant Health after the company reported preliminary Q4 results that were well ahead of consensus estimates. Guardant’s test volume growth and revenue per test were nicely ahead of estimates, the company also achieved its cash burn target for 2023, and noted that its core therapy selection business has achieved cash flow breakeven, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on GH:
- Guardant Health names Terilyn Juarez Monroe as chief people officer
- Guardant Health sells 3.387M shares at $26.77 in registered direct offering
- Guardant Health announces tentative date of FDA panel review of Shield test
- Guardant Health initiated with neutral view at Guggenheim, here’s why
- Guardant Health initiated with neutral view at Wolfe Research, here’s why
